Your session is about to expire
← Back to Search
Favezelimab + Pembrolizumab/Chemotherapy/Lenvatinib for Cancer
Study Summary
This trial is testing favezelimab as a possible treatment for people with metastatic solid tumors. The study will look at different doses of the drug and how well it works when used alone or in combination with other drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had cancer treatment in the last 4 weeks or still have side effects from treatments over 4 weeks ago.I have had a stem cell or bone marrow transplant.I have not received a live-virus vaccine in the last 30 days.You had a bad allergic reaction to a similar type of medication in the past.I had cancer before, but it's been treated and I've been cancer-free for 5 years, except for certain skin, bladder, or cervical cancers.I am fully active or restricted in physically strenuous activity but can do light work.I have had pneumonitis treated with steroids or have it now.My organs are functioning well.You have mental health or substance abuse problems that could make it difficult for you to follow the study's instructions.My partner and I agree to use birth control during and after my treatment.I have been treated with a drug targeting the LAG-3 receptor before.I have HIV or active Hepatitis B or C.I will not need any cancer treatment other than the study's while participating.My cancer has spread and this was confirmed through testing.I have heart disease that limits my daily activities.I am currently being treated for an infection.I have fluid buildup in my abdomen or chest but am stable after treatment.I stopped an immune therapy due to a severe side effect.I have an immune system disorder or am on high-dose steroids or other drugs that weaken my immune system.You have an ongoing autoimmune disease or a past history of autoimmune disease, except for vitiligo or childhood asthma/allergies that you have outgrown.I have cancer that has spread to my brain or spinal cord.
Frequently Asked Questions
In what number of health centers is this clinical trial taking place?
"Patients are being recruited at 8 different clinics, including Call for Information (Investigational Site 0001) in San Antonio and Call for Information (Investigational Site 0019) in Denver. Additionally, the trial is also enrolling participants from Rochester, Minnesota (Call for Info - Investigational Site 0020), as well as 6 other sites."
Can you please provide a summary of prior research initiatives involving Favezelimab/Pembrolizumab?
"Currently, there are 1631 clinical trials investigating Favezelimab/Pembrolizumab and 322 of these studies have reached the third phase. Most of them take place in Guangzhou, Guangdong; however, a total 61802 research sites around the globe are carrying out tests for this treatment."
Are there any limitations on the participant pool for this clinical research project?
"At present, the trial is not accepting new patients. This study was first posted on May 2nd 2016 and last updated August 31st 2022. However, if you are searching for other trials that accommodate cancer sufferers there are 2379 active studies; similarly 1631 clinical trials recruiting participants with Favezelimab/Pembrolizumab as a treatment have been identified."
Are there any openings presently available to take part in this investigation?
"According to clinicaltrials.gov, this particular medical trial is not recruiting participants at the moment; however, it was initially posted on May 2nd 2016 and last updated on August 31st 2022. Fortunately, there are 4010 other trials that presently have open enrollment slots for patients."
What potential risks are associated with Favezelimab/Pembrolizumab?
"Since this is only a Phase 1 trial, which reflects limited data on safety and efficacy, Favezelimab/Pembrolizumab received the lowest rating of 1."
What health conditions are Favezelimab/Pembrolizumab usually employed to address?
"Favezelimab/Pembrolizumab is suitable for treating malignant tumors, pervasive melanomas, and cells with high microsatellite instability."
Share this study with friends
Copy Link
Messenger